346 related articles for article (PubMed ID: 34011405)
1. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.
Dinca SC; Greiner D; Weidenfeld K; Bond L; Barkan D; Jorcyk CL
Breast Cancer Res; 2021 May; 23(1):56. PubMed ID: 34011405
[TBL] [Abstract][Full Text] [Related]
2. Oncostatin M binds to extracellular matrix in a bioactive conformation: implications for inflammation and metastasis.
Ryan RE; Martin B; Mellor L; Jacob RB; Tawara K; McDougal OM; Oxford JT; Jorcyk CL
Cytokine; 2015 Mar; 72(1):71-85. PubMed ID: 25622278
[TBL] [Abstract][Full Text] [Related]
3. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
[TBL] [Abstract][Full Text] [Related]
4. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
[TBL] [Abstract][Full Text] [Related]
5. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis.
Peng DH; Ungewiss C; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Uraoka N; Mino B; Behrens C; Wistuba II; Han RI; Wanna CA; Fahrenholtz M; Grande-Allen KJ; Creighton CJ; Gibbons DL
Oncogene; 2017 Apr; 36(14):1925-1938. PubMed ID: 27694892
[TBL] [Abstract][Full Text] [Related]
6. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
7. LOXL2 in cancer: regulation, downstream effectors and novel roles.
Wen B; Xu LY; Li EM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188435. PubMed ID: 32976981
[TBL] [Abstract][Full Text] [Related]
8. Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer.
West NR; Murphy LC; Watson PH
Endocr Relat Cancer; 2012 Apr; 19(2):181-95. PubMed ID: 22267707
[TBL] [Abstract][Full Text] [Related]
9. Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.
Smigiel JM; Parameswaran N; Jackson MW
Mol Cancer Res; 2017 Apr; 15(4):478-488. PubMed ID: 28053127
[TBL] [Abstract][Full Text] [Related]
10. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma.
Alonso-Nocelo M; Ruiz-Cañas L; Sancho P; Görgülü K; Alcalá S; Pedrero C; Vallespinos M; López-Gil JC; Ochando M; García-García E; David Trabulo SM; Martinelli P; Sánchez-Tomero P; Sánchez-Palomo C; Gonzalez-Santamaría P; Yuste L; Wörmann SM; Kabacaoğlu D; Earl J; Martin A; Salvador F; Valle S; Martin-Hijano L; Carrato A; Erkan M; García-Bermejo L; Hermann PC; Algül H; Moreno-Bueno G; Heeschen C; Portillo F; Cano A; Sainz B
Gut; 2023 Feb; 72(2):345-359. PubMed ID: 35428659
[TBL] [Abstract][Full Text] [Related]
11. Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.
Salvador F; Martin A; López-Menéndez C; Moreno-Bueno G; Santos V; Vázquez-Naharro A; Santamaria PG; Morales S; Dubus PR; Muinelo-Romay L; López-López R; Tung JC; Weaver VM; Portillo F; Cano A
Cancer Res; 2017 Nov; 77(21):5846-5859. PubMed ID: 28720577
[TBL] [Abstract][Full Text] [Related]
12. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution.
Barker HE; Chang J; Cox TR; Lang G; Bird D; Nicolau M; Evans HR; Gartland A; Erler JT
Cancer Res; 2011 Mar; 71(5):1561-72. PubMed ID: 21233336
[TBL] [Abstract][Full Text] [Related]
13. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
[TBL] [Abstract][Full Text] [Related]
14. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.
Moon HJ; Finney J; Xu L; Moore D; Welch DR; Mure M
J Biol Chem; 2013 Oct; 288(42):30000-30008. PubMed ID: 24014025
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
16. Tumor-secreted LOXL2 activates fibroblasts through FAK signaling.
Barker HE; Bird D; Lang G; Erler JT
Mol Cancer Res; 2013 Nov; 11(11):1425-36. PubMed ID: 24008674
[TBL] [Abstract][Full Text] [Related]
17. Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
Araujo AM; Abaurrea A; Azcoaga P; López-Velazco JI; Manzano S; Rodriguez J; Rezola R; Egia-Mendikute L; Valdés-Mora F; Flores JM; Jenkins L; Pulido L; Osorio-Querejeta I; Fernández-Nogueira P; Ferrari N; Viera C; Martín-Martín N; Tzankov A; Eppenberger-Castori S; Alvarez-Lopez I; Urruticoechea A; Bragado P; Coleman N; Palazón A; Carracedo A; Gallego-Ortega D; Calvo F; Isacke CM; Caffarel MM; Lawrie CH
J Clin Invest; 2022 Apr; 132(7):. PubMed ID: 35192545
[TBL] [Abstract][Full Text] [Related]
18. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.
Ahn SG; Dong SM; Oshima A; Kim WH; Lee HM; Lee SA; Kwon SH; Lee JH; Lee JM; Jeong J; Lee HD; Green JE
Breast Cancer Res Treat; 2013 Aug; 141(1):89-99. PubMed ID: 23933800
[TBL] [Abstract][Full Text] [Related]
19. The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.
Adrian-Segarra JM; Schindler N; Gajawada P; Lörchner H; Braun T; Pöling J
J Biol Chem; 2018 May; 293(18):7017-7029. PubMed ID: 29511087
[TBL] [Abstract][Full Text] [Related]
20. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.
West NR; Murray JI; Watson PH
Oncogene; 2014 Mar; 33(12):1485-94. PubMed ID: 23584474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
